David Rodman's most recent trade in Mineralys Therapeutics Inc was a trade of 416 Common Stock done at an average price of $15.4 . Disclosure was reported to the exchange on Jan. 20, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.44 per share. | 20 Jan 2026 | 416 | 50,853 | - | 15.4 | 6,423 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2026 | 416 | 5,834 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.10 per share. | 20 Jan 2026 | 416 | 50,437 | - | 32.1 | 13,354 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.61 per share. | 13 Jan 2026 | 11,367 | 50,437 | - | 32.6 | 370,645 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.75 per share. | 13 Jan 2026 | 7,709 | 61,804 | - | 32.8 | 252,470 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.25 per share. | 13 Jan 2026 | 4,167 | 69,513 | - | 14.3 | 59,380 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2026 | 4,167 | 104,167 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.20 per share. | 13 Jan 2026 | 3,542 | 65,346 | - | 10.2 | 36,128 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2026 | 3,542 | 131,042 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 09 Jan 2026 | 6,348 | 68,152 | - | 1.1 | 6,856 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.32 per share. | 09 Jan 2026 | 6,348 | 61,804 | - | 32.3 | 205,143 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2026 | 6,348 | 38,092 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 33.27 per share. | 09 Jan 2026 | 2,170 | 61,804 | - | 33.3 | 72,196 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2026 | 2,170 | 28,218 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 09 Jan 2026 | 2,170 | 63,974 | - | 16 | 34,720 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 34.83 per share. | 02 Jan 2026 | 139,245 | 115,274 | - | 34.8 | 4,849,555 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.87 per share. | 02 Jan 2026 | 70,037 | 69,188 | - | 35.9 | 2,511,919 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.25 per share. | 02 Jan 2026 | 67,473 | 254,519 | - | 14.2 | 961,490 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 67,473 | 108,334 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 02 Jan 2026 | 53,630 | 187,046 | - | 16 | 858,080 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 53,630 | 30,388 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.53 per share. | 02 Jan 2026 | 53,470 | 61,804 | - | 35.5 | 1,899,554 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 02 Jan 2026 | 28,038 | 97,226 | - | 1.1 | 30,281 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 28,038 | 44,440 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.20 per share. | 02 Jan 2026 | 26,069 | 133,416 | - | 10.2 | 265,904 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 26,069 | 134,584 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.25 per share. | 02 Jan 2026 | 24,193 | 139,225 | - | 14.2 | 344,750 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 24,193 | 175,807 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 02 Jan 2026 | 20,168 | 115,032 | - | 16 | 322,688 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 20,168 | 84,018 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.44 per share. | 02 Jan 2026 | 10,121 | 107,347 | - | 15.4 | 156,268 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 10,121 | 6,250 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 02 Jan 2026 | 10,053 | 81,888 | - | 1.1 | 10,857 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 10,053 | 72,478 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.20 per share. | 02 Jan 2026 | 9,347 | 94,864 | - | 10.2 | 95,339 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 9,347 | 160,653 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.44 per share. | 02 Jan 2026 | 3,629 | 85,517 | - | 15.4 | 56,032 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 3,629 | 16,371 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 43.01 per share. | 15 Oct 2025 | 10,369 | 71,155 | - | 43.0 | 445,982 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.90 per share. | 15 Sep 2025 | 9,302 | 83,589 | - | 35.9 | 333,946 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 36.47 per share. | 15 Sep 2025 | 2,065 | 81,524 | - | 36.5 | 75,320 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.93 per share. | 12 Aug 2025 | 11,365 | 92,891 | - | 12.9 | 146,987 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 12 Aug 2025 | 6,349 | 104,256 | - | 1.1 | 6,857 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2025 | 6,349 | 82,531 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 14.59 per share. | 14 Jul 2025 | 11,366 | 97,907 | - | 14.6 | 165,879 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jul 2025 | 6,349 | 88,880 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 14 Jul 2025 | 6,349 | 109,273 | - | 1.1 | 6,857 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 14.60 per share. | 12 Jun 2025 | 11,366 | 101,651 | - | 14.6 | 165,931 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2025 | 6,348 | 95,229 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 12 Jun 2025 | 6,348 | 113,017 | - | 1.1 | 6,856 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.29 per share. | 14 May 2025 | 11,366 | 106,669 | - | 15.3 | 173,774 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 12 May 2025 | 6,349 | 118,035 | - | 1.1 | 6,857 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 May 2025 | 6,349 | 101,577 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 14.83 per share. | 14 Apr 2025 | 8,400 | 111,686 | - | 14.8 | 124,572 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2025 | 6,348 | 107,926 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 14 Apr 2025 | 6,348 | 123,052 | - | 1.1 | 6,856 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 13.69 per share. | 14 Apr 2025 | 2,966 | 120,086 | - | 13.7 | 40,613 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 01 Apr 2025 | 30,574 | 141,901 | - | 15.0 | 458,543 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 16.77 per share. | 01 Apr 2025 | 22,406 | 116,704 | - | 16.8 | 375,749 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 16.02 per share. | 01 Apr 2025 | 2,791 | 139,110 | - | 16.0 | 44,717 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 1,606 | 114,274 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 01 Apr 2025 | 1,606 | 172,475 | - | 1.1 | 1,734 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2025 | 6,349 | 115,880 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 12 Mar 2025 | 6,349 | 170,869 | - | 1.1 | 6,857 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 170,000 | 170,000 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 12 Feb 2025 | 6,348 | 164,520 | - | 1.1 | 6,856 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 6,348 | 122,229 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 13 Jan 2025 | 6,349 | 158,172 | - | 1.1 | 6,857 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2025 | 6,349 | 128,577 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 13 Jan 2025 | 5,018 | 151,823 | - | 0.5 | 2,710 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2025 | 5,018 | 0 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2024 | 5,017 | 5,018 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | Rodman David | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 11 Dec 2024 | 5,017 | 146,008 | - | 0.5 | 2,709 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2024 | 5,026 | 134,926 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 11 Nov 2024 | 5,026 | 140,991 | - | 15.0 | 75,398 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 11 Nov 2024 | 5,026 | 146,017 | - | 1.1 | 5,428 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 11 Nov 2024 | 5,017 | 140,991 | - | 0.5 | 2,709 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2024 | 5,017 | 10,035 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.03 per share. | 06 Nov 2024 | 25,482 | 135,974 | - | 15.0 | 383,066 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 06 Nov 2024 | 25,482 | 161,456 | - | 1.1 | 27,521 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Nov 2024 | 25,482 | 139,952 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2024 | 5,352 | 165,434 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 11 Oct 2024 | 5,352 | 135,974 | - | 1.1 | 5,780 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 11 Oct 2024 | 5,017 | 130,622 | - | 0.5 | 2,709 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2024 | 5,017 | 15,052 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2024 | 6,349 | 170,786 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 11 Sep 2024 | 6,349 | 125,605 | - | 1.1 | 6,857 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 11 Sep 2024 | 5,018 | 119,256 | - | 0.5 | 2,710 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2024 | 5,018 | 20,069 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2024 | 6,348 | 177,135 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 12 Aug 2024 | 6,348 | 114,238 | - | 1.1 | 6,856 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2024 | 5,017 | 25,087 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 12 Aug 2024 | 5,017 | 107,890 | - | 0.5 | 2,709 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2024 | 525 | 183,483 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 16 Jul 2024 | 525 | 102,873 | - | 15.0 | 7,876 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 16 Jul 2024 | 525 | 103,398 | - | 1.1 | 567 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 11 Jul 2024 | 6,349 | 102,873 | - | 1.1 | 6,857 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2024 | 6,349 | 184,008 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 11 Jul 2024 | 5,017 | 96,524 | - | 0.5 | 2,709 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2024 | 5,017 | 30,104 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 11 Jun 2024 | 6,349 | 89,729 | - | 1.1 | 6,857 | Common Stock |